Clinical characteristics
| Variable . | N . | DLBCL, N = 42∗ . | MM, N = 10∗ . |
|---|---|---|---|
| Age at CAR T-cell infusion, y | 52 | ||
| Median (IQR) | 65 (48-70) | 69 (65-71) | |
| Number of therapy lines before CAR T-cell infusion | 52 | ||
| 1-3 | 37 (88%) | 2 (20%) | |
| 4-6 | 5 (12%) | 4 (40%) | |
| 7-10 | 0 (0%) | 4 (40%) | |
| Disease status | 52 | ||
| CR | 4 (9.5%) | 0 (0%) | |
| PD | 27 (64%) | 6 (60%) | |
| PR | 7 (17%) | 2 (20%) | |
| SD | 4 (9.5%) | 2 (20%) | |
| ECOG performance status | 52 | ||
| 0 | 18 (43%) | 0 (0%) | |
| 1 | 21 (50%) | 9 (90%) | |
| 2 | 3 (7.1%) | 1 (10%) | |
| CAR T-cell product | 52 | ||
| Idecabtagene vicleucel | 0 (0%) | 9 (90%) | |
| Lisocabtagene maraleucel | 1 (2.4%) | 0 (0%) | |
| Ciltacabtagene autoleucel | 0 (0%) | 1 (10%) | |
| Tisagenlecleucel | 10 (24%) | 0 (0%) | |
| Axicabtagene ciloleucel | 31 (74%) | 0 (0%) | |
| CRS grade | 52 | ||
| Grades 0-1 | 24 (57%) | 5 (50%) | |
| Grade 2 | 14 (33%) | 3 (30%) | |
| Grade 3 | 3 (7.1%) | 2 (20%) | |
| Grade 4 | 1 (2.4%) | 0 (0%) | |
| ICANS grade | 52 | ||
| Grades 0-1 | 28 (67%) | 8 (80%) | |
| Grade 2 | 4 (9.5%) | 1 (10%) | |
| Grade 3 | 7 (17%) | 0 (0%) | |
| Grade 4 | 3 (7.1%) | 1 (10%) | |
| Granulocytes recovery, d | 50 | ||
| Median (IQR) | 13 (10-20) | 11 (10-14) | |
| Not reached (n) | 1 | 1 | |
| Thrombocytes recovery, d | 47 | ||
| Median (IQR) | 0 (0-18) | 7 (0-10) | |
| Not reached (n) | 4 | 1 |
| Variable . | N . | DLBCL, N = 42∗ . | MM, N = 10∗ . |
|---|---|---|---|
| Age at CAR T-cell infusion, y | 52 | ||
| Median (IQR) | 65 (48-70) | 69 (65-71) | |
| Number of therapy lines before CAR T-cell infusion | 52 | ||
| 1-3 | 37 (88%) | 2 (20%) | |
| 4-6 | 5 (12%) | 4 (40%) | |
| 7-10 | 0 (0%) | 4 (40%) | |
| Disease status | 52 | ||
| CR | 4 (9.5%) | 0 (0%) | |
| PD | 27 (64%) | 6 (60%) | |
| PR | 7 (17%) | 2 (20%) | |
| SD | 4 (9.5%) | 2 (20%) | |
| ECOG performance status | 52 | ||
| 0 | 18 (43%) | 0 (0%) | |
| 1 | 21 (50%) | 9 (90%) | |
| 2 | 3 (7.1%) | 1 (10%) | |
| CAR T-cell product | 52 | ||
| Idecabtagene vicleucel | 0 (0%) | 9 (90%) | |
| Lisocabtagene maraleucel | 1 (2.4%) | 0 (0%) | |
| Ciltacabtagene autoleucel | 0 (0%) | 1 (10%) | |
| Tisagenlecleucel | 10 (24%) | 0 (0%) | |
| Axicabtagene ciloleucel | 31 (74%) | 0 (0%) | |
| CRS grade | 52 | ||
| Grades 0-1 | 24 (57%) | 5 (50%) | |
| Grade 2 | 14 (33%) | 3 (30%) | |
| Grade 3 | 3 (7.1%) | 2 (20%) | |
| Grade 4 | 1 (2.4%) | 0 (0%) | |
| ICANS grade | 52 | ||
| Grades 0-1 | 28 (67%) | 8 (80%) | |
| Grade 2 | 4 (9.5%) | 1 (10%) | |
| Grade 3 | 7 (17%) | 0 (0%) | |
| Grade 4 | 3 (7.1%) | 1 (10%) | |
| Granulocytes recovery, d | 50 | ||
| Median (IQR) | 13 (10-20) | 11 (10-14) | |
| Not reached (n) | 1 | 1 | |
| Thrombocytes recovery, d | 47 | ||
| Median (IQR) | 0 (0-18) | 7 (0-10) | |
| Not reached (n) | 4 | 1 |
CR, complete remission; ECOG, Eastern Cooperative Oncology Group; PD, progressive disease; PR, partial remission; SD, stable disease.
n (%).